Advertisement
Horizon Therapeutics To Buyback Up To $500 Mln Of Ordinary Shares
(RTTNews) - Biotechnology company Horizon Therapeutics plc (HZNP) today announced that its Board of Directors authorized the repurchase of up to $500 million of the Company's ordinary shares.
Under the program, the Company may repurchase ordinary shares from time to time on the open market or through privately negotiated transactions or structured repurchase transactions.
As of June 30, 2022, the Company had cash and cash equivalents of $1.89 billion. The Company expects to fund the repurchase of its ordinary shares under the program with existing cash and cash equivalents.
read more
Amgen, Horizon Therapeutics Reach Settlement On FTC Lawsuit; Seeks To Close Acquisition In Q4
Amgen (AMGN) and Horizon Therapeutics plc (HZNP) announced Friday the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. This clears the path to take the final steps to close Amgen's $27.8 billion acquisition of Horizon.
RTTNews
|
Před 726 dny
Horizon Says UPLIZNA Approved By Brazilian Health Regulatory Agency As Monotherapy For NMOSD
Biotechnology company Horizon Therapeutics plc (HZNP) announced Tuesday that the Brazilian Health Regulatory Agency (ANVISA) has approved UPLIZNA as a monotherapy for the treatment of adult patients with NMOSD who are AQP4-IgG+.
RTTNews
|
Před 981 dny
Xeris Biopharma Inks Research Collaboration With Horizon Therapeutics To Develop Teprotumumab
Biopharmaceutical company Xeris Biopharma Holdings, Inc. (XERS) announced Wednesday that it has entered into a research collaboration and option agreement with Horizon Therapeutics plc (HZNP).
RTTNews
|
Před 1008 dny
Horizon Says Phase 2 Trial Of Dazodalibep To Treat Sjögren's Syndrome Met Primary Endpoint
Horizon Therapeutics plc (HZNP) announced Monday that its Phase 2 trial evaluating dazodalibep for the treatment of Sjögren's syndrome met the primary endpoint in patients with moderate-to-high systemic disease activity. Sjögren's syndrome is a disease with no FDA-approved treatments available.
RTTNews
|
Před 1080 dny
Hong Kong Shares Poised To End Two-Day Slide
The Hong Kong stock market has finished lower in consecutive trading days, tumbling almost 630 points or 2.5 percent along the way. The Hang Seng Index now rests just above the 25,200-point plateau although it may find traction on Thursday.
RTTNews
|
Před 17 minutami
China Stock Market May Stop The Bleeding On Thursday
The China stock market has finished lower in two straight sessions, retreating more than 80 points or 2.1 percent along the way. The Shanghai Composite Index now sits just above the 3,800-point plateau although it's due for support on Thursday.
RTTNews
|
Před 32 minutami
Taiwan Stock Market May Extend Winning Streak
The Taiwan stock market has tracked higher in three straight sessions, gathering more than 750 points or 3.1 percent along the way. The Taiwan Stock Exchange now rests just beneath the 24,520-point plateau and it may add to its winnings again on Thursday.
RTTNews
|
Před 1 h 2 min
Singapore Stock Market May Extend Wednesday's Gains
The Singapore stock market bounced higher again on Wednesday, one day after snapping the five-day winning streak in which it had climbed almost 70 points or 1.6 percent. The Straits Times Index now sits just above the 4,245-point plateau and it may pick up steam on Thursday.
RTTNews
|
Před 1 h 32 min
